Streetbeat News

Price Targets

XRAY

Morgan Stanley analyst Erin Wright has maintained an Overweight rating on Dentsply Sirona (NASDAQ:XRAY) but lowered the price target from $47 to $43.

Portfolio Pulse from Benzinga Newsdesk

October 20, 2023 | 12:02 pm

BX

Morgan Stanley analyst Michael Cyprys has maintained an Overweight rating on Blackstone (NYSE:BX) but lowered the price target from $125 to $120.

Portfolio Pulse from Benzinga Newsdesk

October 20, 2023 | 12:00 pm

SYK

Stryker (NYSE:SYK) has received positive analyst ratings in the last quarter, with 3 bullish, 2 somewhat bullish, and 1 indifferent rating. The average 12-month price target for Stryker is $325.0, an increase of 1.78% from the previous average price target of $319.33.

Portfolio Pulse from Benzinga Insights

October 20, 2023 | 12:00 pm

BMY

UBS analyst Trung Huynh has assumed Bristol-Myers Squibb (NYSE:BMY) with a Neutral rating and has lowered the price target to $60.

Portfolio Pulse from Benzinga Newsdesk

October 20, 2023 | 11:57 am

LLY

UBS analyst Trung Huynh has assumed Eli Lilly (NYSE:LLY) with a Buy rating and raised the price target to $710.

Portfolio Pulse from Benzinga Newsdesk

October 20, 2023 | 11:49 am

RUN

Exane BNP Paribas analyst Moses Sutton has initiated coverage on Sunrun (NASDAQ:RUN) with an Outperform rating and a price target of $20.

Portfolio Pulse from Benzinga Newsdesk

October 20, 2023 | 11:37 am

SPWR

Exane BNP Paribas analyst Moses Sutton has initiated coverage on SunPower (NASDAQ:SPWR) with an Underperform rating and a price target of $4.

Portfolio Pulse from Benzinga Newsdesk

October 20, 2023 | 11:29 am

FTNT

Rosenblatt analyst Catharine Trebnick maintains a 'Buy' rating on Fortinet (NASDAQ:FTNT) but has lowered the price target from $90 to $75.

Portfolio Pulse from Benzinga Newsdesk

October 20, 2023 | 11:24 am

HASI

Exane BNP Paribas analyst Moses Sutton has initiated coverage on Hannon Armstrong (NYSE:HASI) with an Outperform rating and a price target of $29.

Portfolio Pulse from Benzinga Newsdesk

October 20, 2023 | 11:12 am

CYTK

HC Wainwright & Co. analyst Joseph Pantginis maintains a 'Buy' rating on Cytokinetics (NASDAQ:CYTK) and raises the price target from $49 to $58.

Portfolio Pulse from Benzinga Newsdesk

October 20, 2023 | 11:10 am